What is Neuraxis's market cap?

Neuraxis (NRXS) has a market capitalization of $89.3M and trades on AMEX.

Who are Neuraxis's competitors?

Neuraxis's key competitors include electroCore, Inc., Ironwood Pharmaceuticals, Inc., Salix Pharmaceuticals, and others. These companies compete in similar markets and product categories.

Who does Neuraxis partner with?

Neuraxis's notable partners include Masimo Corporation, TKBMN, LLC.

Where is Neuraxis headquartered?

Neuraxis is headquartered in United States of America and employs approximately 19 people. It has been publicly traded since 2023.

Neuraxis

NRXS

Neuraxis, Inc. is a growth-stage medical technology company that develops and commercializes proprietary neuromodulation therapies for chronic gastrointestinal disorders.

Market cap

$89.29M+289%

Table of contents

Earnings

Q1 2026 report

May 12, 2026

Revenue$1.6MBeat by $157.9K EPS-$0.18Beat by $0.01

Read the full report

Next report

Sep 17, 2026 (in 2 months)

Revenue estimate$2.0M

EPS estimate-$0.17

Competitors

By market cap

AbbVie$441.54B+33.2%

LivaNova$4.5B+82.4%

Bausch Health Companies$1.8B-28.5%

Ironwood Pharmaceuticals$768.7M+566%

Neuropace, Inc.$578.6M+72.6%

Neuraxis$89.3M+247%

electroCore, Inc.$55.1M+21.9%

Nexalin Technology, Inc.$9.7M-40.3%

By revenue growth

electroCore, Inc.+31.9%

Neuropace, Inc.+18.1%

Ironwood Pharmaceuticals+13.8%

LivaNova+12.4%

AbbVie+9.5%

Bausch Health Companies+8.2%

By net margin

Ironwood Pharmaceuticals28.26%+38.4pp

AbbVie5.79%-1.5pp

Bausch Health Companies-1.88%-9.1pp

LivaNova-16.12%-22.5pp

Neuropace, Inc.-21.67%+7.8pp

electroCore, Inc.-44.08%+2.2pp

Profile

Neuraxis, Inc. is a growth-stage medical technology company that develops and commercializes proprietary neuromodulation therapies for chronic gastrointestinal disorders. The company's core value proposition centers on its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, which provides a drug-free alternative for treating disorders of the gut-brain interaction in both pediatric and adult populations.

Competitive position

Neuraxis holds a first-to-market advantage with the only FDA-cleared PENFS treatment recommended by major pediatric academic society guidelines.

GeographiesUnited States

Customer segmentsPediatric healthcare providers, Gastroenterology clinics, Government healthcare systems

Business modelDirect-to-hospital sales, Medical device manufacturing

SuppliersContract manufacturing services in Indiana and Michigan, Specialized medical component suppliers, Electronic pulse generator manufacturers

CustomersChildren's hospitals, Veterans Affairs (VA) hospitals, Gastroenterology specialty clinics

CountryUnited States of America

Listed2023

Employees19.0

CEOBrian Carrico

SectorHealthcare

IndustryBiotechnology

Websiteneuraxis.com

FilingsSEC EDGAR

Questions, answered.

What is Neuraxis's market cap?: Neuraxis (NRXS) has a market capitalization of $89.3M and trades on AMEX.
Who are Neuraxis's competitors?: Neuraxis's key competitors include electroCore, Inc., Ironwood Pharmaceuticals, Inc., Salix Pharmaceuticals, and others. These companies compete in similar markets and product categories.
Who does Neuraxis partner with?: Neuraxis's notable partners include Masimo Corporation, TKBMN, LLC.
Where is Neuraxis headquartered?: Neuraxis is headquartered in United States of America and employs approximately 19 people. It has been publicly traded since 2023.